OPR - Delayed Quote USD

LXRX Oct 2024 5.000 call (LXRX241018C00005000)

0.1000

0.0000

(0.00%)

At close: April 22 at 11:00 AM EDT

Key Events

Loading Chart for LXRX241018C00005000

9/21 12:03 PM

DELL

Previous Close 0.1000
Open 0.1000
Bid 0.0500
Ask 0.1000
Strike 5.00
Expire Date 2024-10-18
Day's Range 0.1000 - 0.1000
Contract Range --
Volume 70
Open Interest 835

Lexicon Pharmaceuticals to Host 2024 Investor Day

Lexicon Pharmaceuticals to Host 2024 Investor Day

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

15 Hot Penny Stocks On the Move

15 Hot Penny Stocks On the Move